58.18
2.19 (3.91%)
| Penutupan Terdahulu | 55.99 |
| Buka | 55.99 |
| Jumlah Dagangan | 3,066,468 |
| Purata Dagangan (3B) | 2,544,496 |
| Modal Pasaran | 5,544,567,296 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.36 |
| Harga / Jualan (P/S) | 133.62 |
| Harga / Buku (P/B) | 2.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -17,158.84% |
| EPS Cair (TTM) | -4.49 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 71.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.99% |
| Nisbah Semasa (MRQ) | 15.64 |
| Aliran Tunai Operasi (OCF TTM) | -306.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -193.24 M |
| Pulangan Atas Aset (ROA TTM) | -12.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | CRISPR Therapeutics AG | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.0 |
| Purata | 0.13 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 1.69% |
| % Dimiliki oleh Institusi | 76.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Orbis Allan Gray Ltd | 30 Sep 2025 | 4,982,085 |
| Sr One Capital Management, Lp | 30 Sep 2025 | 2,038,763 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 1,389,276 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 93.00 (B of A Securities, 59.85%) | Beli |
| Median | 75.50 (29.77%) | |
| Rendah | 44.00 (Baird, -24.37%) | Pegang |
| Purata | 71.00 (22.04%) | |
| Jumlah | 6 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 57.92 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 26 Nov 2025 | 74.00 (27.19%) | Beli | 53.30 |
| Citigroup | 12 Nov 2025 | 77.00 (32.35%) | Beli | 52.19 |
| Baird | 11 Nov 2025 | 44.00 (-24.37%) | Pegang | 55.21 |
| RBC Capital | 11 Nov 2025 | 50.00 (-14.06%) | Pegang | 55.21 |
| Needham | 10 Nov 2025 | 80.00 (37.50%) | Beli | 54.58 |
| 10 Oct 2025 | 81.00 (39.22%) | Beli | 73.07 | |
| B of A Securities | 17 Oct 2025 | 93.00 (59.85%) | Beli | 69.15 |
| HC Wainwright & Co. | 23 Sep 2025 | 80.00 (37.50%) | Beli | 60.76 |
| JP Morgan | 18 Sep 2025 | 70.00 (20.32%) | Beli | 62.94 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |